In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa ...

First patient dosing in Company’s Phase 2b trial marks pivotal milestone in phage therapy development program targeting ...

UNM health scientists are seeking funding from the Alzheimer's Association and other venture capitalists to launch phase 1 of ...

Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial ...

LUND, SWEDEN / ACCESS Newswire / July 14, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that it has dosed the first patient ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Verastem Oncology releases primary results from phase 2 RAMP 201 trial of Avutometinib in combo with defactinib: Boston Tuesday, July 15, 2025, 09:00 Hrs [IST] Verastem Oncology, ...

Verastem has reported primary analysis data from the Phase II RAMP 201 trial, where the avutometinib combination showed an ORR of 31% ...

Imagion Biosystems is on track to start Phase II clinical trial for HER2 breast cancer after a positive meeting with ... Read ...

Amylyx has presented new exploratory analyses from the Phase II PREVENT and Phase IIb trials of avexitide for PBH treatment.